Background: Pancreatic ductal adenocarcinoma (PDAC) often presents late with nonspecific symptoms, particularly in elderly patients with multiple comorbidities. The “double-duct sign”, characterized by simultaneous dilation of the common bile duct (CBD) and main pancreatic duct (PD), is a radiologic indicator of pancreatic head or peri-ampullary malignancy. Multidisciplinary management is critical to optimize diagnostic accuracy, therapeutic interventions, and patient-centered care. Case Presentation: An 82-year-old female with a history of cerebrovascular accident, hypothyroidism, asthma, osteoarthritis, migraine headaches, gastroesophageal reflux disease, and prior cholecystectomy presented with early satiety, progressive unintentional weight loss over several months, and visible jaundice noted by a friend. Laboratory evaluation revealed marked hyperbilirubinemia and significantly elevated CA 19-9 (~2390 U/mL). Imaging demonstrated a dilated CBD and PD consistent with the double-duct sign and a small mass in the head/uncinate process of the pancreas. ERCP with stent placement relieved the obstruction. EUS-guided fine-needle biopsy confirmed adenocarcinoma. Multidisciplinary involvement, including Gastroenterology, Surgical Oncology, Hematology/Oncology, Pulmonology, Nutrition, and Palliative Care, guided staging, aspiration risk management due to severe esophageal dysmotility, nutritional optimization, and goals-of-care planning. Conclusion: Early recognition of subtle clinical signs, timely endoscopic tissue acquisition, and coordinated multidisciplinary care are essential in managing elderly patients with pancreatic head adenocarcinoma. Comprehensive management mitigates complications, addresses quality-of-life concerns, and aligns treatment with patient-centered goals.
References
[1]
Ahualli, J. (2007) The Double Duct Sign. Radiology, 244, 314-315. https://doi.org/10.1148/radiol.2441041978
[2]
Tripathi, M., Jayarajah, U., Turkington, R., et al. (2018) Pancreatic Ductal Adenocarcinoma: Clinical Diagnosis, Epidemiology, and Outcomes. Medicine (Baltimore), 97, e10350.
[3]
Orth, M., Metzger, P., Gerum, S., et al. (2019) Pancreatic Ductal Adenocarcinoma: Biological Hallmarks, Current Status, and Future Perspectives of Combined Modality Treatment Approaches. Radiation Oncology, 14, Article No. 141. https://doi.org/10.1186/s13014-019-1345-6
Baiu, P.N., et al. (2022) Pancreatic Ductal Adenocarcinoma: Pathogenesis and Screening. Gastroenterology, 162, 1166-1178.
[6]
Hidalgo, M. (2010) Pancreatic Cancer. New England Journal of Medicine, 362, 1605-1617. https://doi.org/10.1056/nejmra0901557
[7]
Elbanna, K.Y., Jang, H.-J. and Kim, T.K. (2020) Imaging Diagnosis and Staging of Pancreatic Ductal Adenocarcinoma: A Comprehensive Review. Insights into Imaging, 11, Article No. 58. https://doi.org/10.1186/s13244-020-00861-y
[8]
Lai, Z. and Yu, X. (2023) Update on Management of Pancreatic Ductal Adenocarcinoma. Cancer Communications (London, England), 43, 109-124.
[9]
Ko, S., Kim, T., Song, T., etal. (2022) Prognosis and Clinical Characteristics of Patients with Pancreatic Ductal Adenocarcinoma Diagnosed by Endoscopic Ultrasonography but Indeterminate on Computed Tomography. Gut Liver, 16, 474-482. https://doi.org/10.5009/gnl210123
[10]
Lee, K. J., et al. (2021) Prognosis of Pancreatic Ductal Adenocarcinoma Diagnosed by Endoscopic Ultrasonography. Gut and Liver, 15, 541-551.
[11]
Luboldt, W. and de Geus, S.W.L. (2019) Pancreatic Ductal Adenocarcinoma: Treatment Hurdles and Tumor Microenvironment. WorldJournalofGastroenterology, 25, 215-232.
[12]
Muniraj, T., Jamidar, P.A. and Aslanian, H.R. (2013) Pancreatic Cancer: A Comprehensive Review and Update. Disease-a-Month, 59, 368-402. https://doi.org/10.1016/j.disamonth.2013.08.001
[13]
Ten Berge, J.C., Suker, M., Bruno, M.J., etal. (2015) Are a Double Duct Sign or Endoscopic Biopsies Reliable Predictors of Malignancy in Periampullary Lesions. Digestive Surgery, 32, 306-311. https://doi.org/10.1159/000380959
O’Neill, M.J. and Greenberg, D.L. (2000) Double-Duct Sign Reassessment in ERCP. AJRAmericanJournalofRoentgenology, 174, 31-35.
[16]
Oterdoom, L.H., van Weyenberg, S.J. and de Boer, N.K. (2013) Double-Duct Sign: Do Not Forget Gallstones. JournalofGastrointestinalandLiverDiseases, 22, 491-494.
[17]
Sachs, T. and Lin, P.C. (2024) Pancreatic Ductal Adenocarcinoma: Applications of AI and Machine Learning. Cancers (Basel), 16, Article 2240.
[18]
Verma, C. and Kaur, D. (2023) Current and Emerging Treatment Options for Pancreatic Ductal Adenocarcinoma. JournalofClinicalMedicine, 14, Article 1129. https://doi.org/10.3390/jcm14041129
[19]
Rozengurt, E. and Eibl, G. (2026) Pancreatic Cancer: Molecular Pathogenesis and Emerging Therapeutic Strategies. Signal Transduction and Targeted Therapy, 11, Article No. 6. https://doi.org/10.1038/s41392-025-02499-y
[20]
Vareedayah, A.A., Alkaade, S. and Taylor, J.R. (2018) Pancreatic Adenocarcinoma. Missouri Medicine, 115, 230-235. https://pmc.ncbi.nlm.nih.gov/articles/PMC6140147/